Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 577 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline solution for intravenous infusion Clear all
Completed Phase 2 Interventional Results available

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

NCT00935883
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Eculizumab, Saline
Drug
Lead sponsor
Philip J. Rosenfeld, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Angiotensin-(1-7) Cardiovascular Effects in Aging

NCT05301192
View directory record Official record
Conditions
Aging
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Recruiting Phase 4 Interventional

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

NCT04166877
View directory record Official record
Conditions
Trauma, Acute Pain
Interventions
Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 17, 2026, 4:55 AM EDT
Withdrawn Phase 4 Interventional

A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients

NCT02336308
View directory record Official record
Conditions
Thermal Hyperalgesia, Anxiety, Pain
Interventions
Ketamine, Placebo, Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

NCT00089453
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

NCT02725957
View directory record Official record
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 17, 2026, 4:55 AM EDT
Recruiting Phase 2 Interventional

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

NCT04042844
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
BRTX-100, Saline
Biological · Drug
Lead sponsor
BioRestorative Therapies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 1 Interventional

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

NCT05547906
View directory record Official record
Conditions
Solid Tumor
Interventions
ASCA101
Drug
Lead sponsor
MetaFines
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 17, 2026, 4:55 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

NCT04328337
View directory record Official record
Conditions
Obesity
Interventions
Intralipid, 20% Intravenous Emulsion, Placebos
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 4:55 AM EDT
Recruiting Not applicable Interventional

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

NCT07225205
View directory record Official record
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
lenvatinib, pembrolizumab, saline placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 17, 2026, 4:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Providing "Good Sleep" for ICU Sedation

NCT01342328
View directory record Official record
Conditions
Sleep Disorders
Interventions
Normal saline infusion, Dexmedetomidine, Propofol
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 17, 2026, 4:55 AM EDT
Withdrawn Not applicable Interventional

Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients

NCT00709293
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Heart Transplantation
Interventions
Anti-Thymocyte Globulin, Normal Saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 4 Interventional

Sleep Intervention During Acute Lung Injury

NCT01050699
View directory record Official record
Conditions
Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Dexmedetomidine, Midazolam and Fentanyl
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 17, 2026, 4:55 AM EDT
Terminated Phase 1 Interventional

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

NCT01161641
View directory record Official record
Conditions
Protein Losing Enteropathy
Interventions
ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

NCT01194414
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of SNF472 for Calciphylaxis

NCT04195906
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Experimental: SNF472, Placebo Comparator: Placebo, Experimatenl SNF472 (Open-label)
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • El Centro, California • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 17, 2026, 4:55 AM EDT
Completed Phase 3 Interventional Results available

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01421511
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FA, Linezolid
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 17, 2026, 4:55 AM EDT